Israeli Prime Minister Naftali Bennett announced the findings during a Jan. 4 news conference, saying the early results “demonstrate a much higher level of protection than without the fourth dose, both in relation to infection and the spread of the virus and in relation to severe morbidity.”
The findings were released after Israel became the first country to broadly roll out fourth doses for healthcare workers and people 60 and older Jan. 2.
Researchers from Israel’s Sheba Medical Center led the study, which involved 150 medical workers who had all previously received the Pfizer vaccine. The initial analysis screened for adverse reactions to the fourth shot, and found side effects were similar to those after the initial doses.
A secondary analysis looked at antibody levels one week after the second boosters were administered. The early findings indicate the shot led to a fivefold jump in antibodies. Sheba Medical Center is also planning a similar trial in which participants who’ve received three doses of Pfizer’s vaccine will receive an extra dose of Moderna’s shot.
To read the full Wall Street Journal article, click here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
